...
首页> 外文期刊>Journal of Ayurveda and Integrative Medicine >A clinical study on Pandu Roga, iron deficiency anemia, with Trikatrayadi Lauha suspension in children
【24h】

A clinical study on Pandu Roga, iron deficiency anemia, with Trikatrayadi Lauha suspension in children

机译:儿童潘卡罗加,铁缺乏性贫血与三卡特拉雅地劳哈混悬液的临床研究

获取原文
           

摘要

Context:Nutritional iron deficiency is the most common cause of anemia in India. The nearest correlation of iron deficiency anemia (IDA) can be made with Pandu Roga in Ayurveda. As the IDA is a very common prevalent disease in the society and the side effects of oral allopathic iron preparations are very common, therefore to get a better alternative, an Ayurvedic herbomineral medicine, the Trikatrayadi Lauha, was subjected to a clinical trial in children suffering from IDA.Aim: Evaluation of safety and efficacy of the compound Trikatrayadi Lauha suspension in children with IDA.Settings and Design:Randomized, double-blind placebo-controlled clinical study.Materials and Methods:The study was conducted on 123 children of IDA for a period of 10 weeks. Clinical features and hematological parameters were documented before, during and after treatment.Statistical Analysis Used: Observations of the study were analyzed and findings were evaluated by using statistical methods (Student′s t test)Results: The present study shows that the trial drug Trikatrayadi Lauha suspension is effective to improve clinical features and hematological parameters significantly. The medicine is effective to increase the hemoglobin level 1.94 g/dL (8.52 -10.46 g/dL, P < 0.001) in 5 weeks and 3.33g/dL (8.52 -11.85g/dL, P < 0.001) in 10 weeks. No adverse effect of the trial drug was observed during the study.Conclusions:The results suggest that Trikatrayadi Lauha is significantly effective in the management of IDA in children.
机译:背景:营养性铁缺乏症是印度贫血的最常见原因。缺铁性贫血(IDA)与阿育吠陀的Pandu Roga最为相关。由于IDA是社会上非常普遍的普遍疾病,口服同种异体铁制剂的副作用非常普遍,因此,为了寻求更好的替代方法,阿育吠陀草药植物药Trikatrayadi Lauha已在患有儿童的儿童中接受了临床试验目的:评价复方三卡妥拉地(Trikatrayadi Lauha)混悬液对IDA患儿的安全性和有效性。设置与设计:随机,双盲安慰剂对照临床研究。材料与方法:该研究针对123名IDA患儿进行了研究。为期10周。在治疗前,治疗中和治疗后记录临床特征和血液学参数。使用统计分析:分析研究的观察结果,并使用统计学方法评估研究结果(Student'st检验)结果:本研究表明试验药物Trikatrayadi Lauha混悬液可有效改善临床特征和血液学参数。该药物可在5周内有效增加血红蛋白水平1.94 g / dL(8.52 -10.46 g / dL,P <0.001)和在10周内增加3.33g / dL(8.52 -11.85g / dL,P <0.001)。在研究过程中未观察到试验药物的不良反应。结论:结果表明,Trikatrayadi Lauha在儿童IDA的治疗中有效。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号